Atea ASA - share buyback
Oslo, 26 November
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
141,086NOK
2,24%
Echtzeit-Aktienkurs Atea ASA
Bid:
Ask:
Nachrichten zur Atea ASA Aktie
Atea ASA - share buyback
Oslo, 13 November
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Atea ASA - share buyback
Oslo, 30 October
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Presentation of 3[rd] quarter 2024 results
Atea ASA will present its 3[rd] quarter 2024 financial results on Wednesday, 23 October 2024 at 08:00 CEST.
The presentation will…
Atea Share Savings Program – notification of trade
Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…
Presentation of 2[nd] quarter 2024 results
Atea ASA will present its 2[nd] quarter 2024 financial results on Friday, 12 July 2024 at 08:00 CEST.
The presentation will…
Atea earns platinum-level sustainability award for fifth consecutive year
For the fifth consecutive year, Atea ASA has earned the highest (“platinum”) rating in environmental and social performance by EcoVadis,…
Ex dividend NOK 3.50 today
The shares in Atea ASA will be traded ex dividend NOK 3.50 as from today, 22 May 2024.
For further information, please…
Atea Share Savings Program – notification of trade
Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…
Mandatory notification of trade
On April 26, the following transactions took place in Atea ASA (the Company):
1. Exercise of stock options
Employees of the Atea…
Presentation of 1[st] quarter 2024 results
Atea ASA will present its 1[st] quarter 2024 financial results on Thursday, 25 April 2024 at 08:00 CEST.
The presentation will…
Grant of share options to primary insiders in Atea ASA
On 8 April 2024, key employees in the Atea Group were granted share options in Atea ASA.
The following primary insiders…
Atea ASA 2023 Annual Report in ESEF format
The company publishes its annual financial statements in European Single
Electronic Format (ESEF), available as an attachment to this release.
The 2023…
Key information relating to cash dividend to be paid by Atea ASA
The Board of Atea ASA has proposed cash dividend with two payments, and with following key details:
Dividend amount: …
Atea Share Savings Program – notification of trade
Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…
Mandatory notification of trade
On February 9, the following transactions took place in Atea ASA (the Company):
1. Exercise of stock options
Employees of the Atea…
Presentation of 4[th] quarter 2023 results
Atea ASA will present its 4[th] quarter 2023 financial results on Thursday, 8 February 2024 at 08:00 CEST.
The presentation will…
Ex dividend NOK 3.125 today
The shares in Atea ASA will be traded ex dividend NOK 3.125 as from today, 20 November 2023.
For further information, please…
Key information relating to cash dividend to be paid by Atea ASA
The Board of Atea ASA has proposed a cash dividend with the following key details:
Dividend amount: …
Atea Share Savings Program – notification of trade
Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…
Mandatory notification of trade
On October 20, the following transactions took place in Atea ASA (the Company):
1. Exercise of stock options
Employees of the Atea…
Presentation of 3[rd] quarter 2023 results
Atea ASA will present its 3[rd] quarter 2023 financial results on Thursday, 19 October 2023 at 08:00 CEST.
The presentation will…
Atea Pharmaceuticals downgraded to underweight from neutral at J.P. Morgan
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Atea Share Savings Program – notification of trade
Reference is made to the stock exchange notice dated June 6, 2023 regarding the launch and terms of the Atea…
Atea Pharmaceuticals GAAP EPS of -$0.34 beats by $0.15
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q Atea Pharmaceuticals, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Correction - Mandatory notification of trade
With reference to stock announcement dated 18 July 2023. The number of shares acquired should be 140,000, and not 20,000…
Mandatory notification of trade
On July 18, 2023, Systemintegration ApS acquired 20,000 shares in Atea ASA at a price of NOK 136.83. Board member…
Atea Q2 2023 financial report and presentation
Atea reported strong revenue growth, higher operating profit and solid cash flow from operations in Q2 2023.
· Strong…
Form 8-K Atea Pharmaceuticals, For: Jun 16
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Atea earns platinum-level sustainability award for fourth consecutive year
For the fourth consecutive year, Atea ASA has earned the highest (“platinum”) rating in environmental and social performance by EcoVadis,…
Atea Share Savings Program – notification of trade
Atea ASA has established an Employee Share Savings Program (the “Program”), which is open to all employees of the Atea…
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Atea rejects takeover offer from Tang Capital Partners
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Atea Pharmaceuticals Rejects Buyout Offer
Atea Pharmaceuticals Rejects Buyout Offer...…
Lordstown Motors, Atea Pharmaceuticals See Activist Investor Action
Lordstown Motors’ former CEO Steve burns lowered his stake in the maker of electric trucks. Atea Pharmaceuticals is evaluating an…
Atea Pharma Confirms Receipt of Unsolicited Proposal; Shares Rise
Atea Pharma Confirms Receipt of Unsolicited Proposal; Shares Rise...…
Atea Pharmaceuticals Up 35% on Buyout Proposal From Tang Capital
Atea Pharmaceuticals Up 35% on Buyout Proposal From Tang Capital...…
Atea Pharmaceuticals jumps on $5.75 a share takeover offer from Tang Capital
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Atea Pharmaceuticals GAAP EPS of -$0.43 beats by $0.07
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Loan agreement with European Investment Bank (EIB)
Reference is made to the stock exchange notice dated April 27, 2023 regarding a new loan agreement with the European…
New Chairman of Atea ASA
The Board of Directors of Atea ASA has elected Sven Madsen (b. 1964) to serve as Chairman of the Board. …
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Mandatory notification of trade
On April 28, the following transactions took place in Atea ASA (the Company):
1. Exercise of stock options
Employees of the Atea…
Ex dividend NOK 3.125 today
The shares in Atea ASA will be traded ex dividend NOK 3.125 as from today, 28 April 2023.
For further information, please…
Annual General Meeting held in Atea ASA
The Annual General Meeting in Atea ASA was held on 27 April 2023. All issues were resolved in accordance with…
Loan agreement with European Investment Bank (EIB)
Atea ASA has entered into a new loan agreement for EUR 50,000,000 with the European Investment Bank. Atea will draw…
Atea Q1 2023 financial report and presentation
Atea reported another consecutive quarter of strong sales growth, record profits and solid cash flow from operations in Q1 2023.
…
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Presentation of 1[st] quarter 2023 results
Atea ASA will present its 1[st] quarter 2023 financial results on Thursday, 27 April 2023 at 08:00 CEST.
The presentation will…